56 results
8-K
EX-99.1
SDGR
Schrödinger, Inc.
31 Jul 24
Schrödinger Reports Strong Second Quarter 2024 Financial Results
4:06pm
tumors. The dose-escalation study is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity
PRE 14A
SDGR
Schrödinger, Inc.
11 Apr 24
Preliminary proxy
7:52am
and completed a Phase 1 clinical trial of SGR-1505 in 73 healthy volunteers to gather additional data, including data relating to the safety
8-K
EX-1.1
qjkuot85uw8y
28 Feb 24
Entry into a Material Definitive Agreement
6:15pm
S-3ASR
EX-1.2
4q7y1rt0s 6b7284vo5
28 Feb 24
Automatic shelf registration
5:30pm
8-K
EX-99.1
2p040f90 kbw
1 Nov 23
Schrödinger Reports Third Quarter 2023 Financial Results
4:00pm
8-K/A
EX-99.1
y73ua2gasoct26my69ps
3 Aug 23
Schrödinger Reports Second Quarter 2023 Financial Results
5:10pm
8-K
EX-99.1
1z01u0v3cf9j7f1f5
2 Aug 23
Schrödinger Reports Second Quarter 2023 Financial Results
4:01pm
8-K
EX-1.1
mvgj315myse886qukb2h
24 May 23
Entry into a Material Definitive Agreement
4:37pm
8-K
EX-99.1
iid4obcq843
4 May 23
Schrödinger Reports Strong First Quarter 2023 Financial Results
4:01pm
8-K
EX-3.1
vzslakhh
13 Apr 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
EX-99.1
dngyxjim
3 Nov 22
Schrödinger Reports Third Quarter 2022 Financial Results
4:01pm